Literature DB >> 4054197

Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden.

K Griffiths, D G McDevitt, M Andrew, I Baksaas, P K Lunde, U Bergman, A Wessling, F Sjöqvist.   

Abstract

The amount of antihypertensive and antidiabetic drugs based of defined daily doses per 1000 inhabitants per day varies two to three fold between Northern Ireland, Norway, and Sweden. We explored whether variations based on the universally applied defined daily doses might be accounted for by national differences in the actual average prescribed daily doses. Use of prescribed daily doses for antihypertensive drugs resulted in Northern Irish and Norwegian consumption figures which were respectively 40 and 21% lower than the Swedish one, compared to 38 and 25% when defined daily doses were used. The effect of population age-sex differences on the gross defined daily doses per 1000 inhabitants per day figures was determined by applying the Northern Irish or Norwegian age-sex group proportions to Swedish age-sex specific sales data. Taking population differences into account would have resulted in antihypertensive drug use being 21 rather than 38% less in Northern Ireland and 18 rather than 25% less in Norway. Also adjustment for prescribed daily doses left an unexplained difference of 23% between Sweden and Northern Ireland and 14% between Sweden and Norway. For oral antidiabetics use of prescribed daily doses resulted in a Northern Irish - Swedish difference of 62% compared to 67% when defined daily doses were used. Simultaneous adjustment for population differences and prescribed to defined daily dose variations left a 52% difference.

Mesh:

Substances:

Year:  1985        PMID: 4054197     DOI: 10.1007/BF00547360

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Patterns in drug utilization--national and international aspects: antihypertensive drugs.

Authors:  I Baksaas
Journal:  Acta Med Scand Suppl       Date:  1984

2.  A community pharmacy-based survey of antihypertensive and antidiabetic drug dosages in Northern Ireland.

Authors:  K Griffiths; D G McDevitt
Journal:  J Clin Hosp Pharm       Date:  1983-06

3.  Utilization of antidiabetic drugs in the Island of Gotland, Sweden: agreement between wholesale figures and prescription data.

Authors:  U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

4.  Prescription of hypotensives in general practice: a study of 4 Norwegian counties in October 1975.

Authors:  I Baksaas; P Fugelli; I K Halvorsen; P K Lunde; K Naess
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden.

Authors:  U Bergman; P Elmes; M Halse; T Halvorsen; H Hood; P K Lunde; F Sjöqvist; O L Wade; B Westerholm
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

6.  Psychotropic drug use in Northern Ireland 1966-80: prescribing trends, inter- and intra-regional comparisons and relationship to demographic and socioeconomic variables.

Authors:  D J King; K Griffiths; P M Reilly; J D Merrett
Journal:  Psychol Med       Date:  1982-11       Impact factor: 7.723

  6 in total
  11 in total

Review 1.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

Review 2.  Impact of drug usage review on drug utilisation.

Authors:  J L Blackburn
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

Review 3.  Pharmaco-epidemiological perspectives.

Authors:  U Bergman
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

4.  The use of drugs in Estonia compared to the Nordic countries.

Authors:  R A Kiivet; U Bergman; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators.

Authors:  H McGavock; C H Webb; G D Johnston; E Milligan
Journal:  BMJ       Date:  1993-10-30

Review 6.  Utilisation of drugs for diabetes mellitus.

Authors:  H I Feldman; B L Strom
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

7.  Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

Authors:  K Griffiths; D G McDevitt; M Andrew; I Baksaas; A Helgeland; J Jervell; P K Lunde; K Oydvin; I Agenäs; U Bergman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Age standardisation of drug utilisation: comparisons of different methods using cardiovascular drug data from Sweden and Spain.

Authors:  J Merlo; J Ranstam; L Råstam; A Wessling; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  The intriguing future of pharmacoepidemiology.

Authors:  Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

10.  Drug utilization by the 30-64 year-old people in two cities in the Federal Republic of Germany in 1984.

Authors:  P Tennis
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.